SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'

The company announced an in-licensing agreement to bring a near-commercial drug candidate directly to the U.S., targeting a commercial launch as early as 2029. Under the deal, upfront and milestone payments related to its Kv7 platform total up to $795M, with additional tiered payments referenced. The agreement supports a clearer U.S. development/commercialization path and increases potential value from the Kv7 pipeline.